Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention
Christian W. Johnson, Deborah L. Burkhart, Kevin M. Haigis
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 913-923
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Oleg Timofeev, Philippe Giron, Steffen Lawo, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 19
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 35
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
Xiaoshen Ma, David L. Sloman, Ruchia Duggal, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11024-11052
Closed Access | Times Cited: 11
Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer
Yanguo Shang, M. Pang, Shengnan Fu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117391-117391
Closed Access | Times Cited: 1
The Predictive and Prognostic Role of RAS–RAF–MEK–ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets
Andrea Rocca, Luca Braga, Maria Concetta Volpe, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5306-5306
Open Access | Times Cited: 28
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Marco Tonello, Dario Baratti, Paolo Sammartino, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102976-102976
Open Access | Times Cited: 6
In Silico Strategies for Designing of Peptide Inhibitors of Oncogenic K-Ras G12V Mutant: Inhibiting Cancer Growth and Proliferation
Mehreen Ghufran, Haider Ali Khan, Mehran Ullah, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4884-4884
Open Access | Times Cited: 23
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Lindor Qunaj, Michael May, Alfred I. Neugut, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Extrauterine Mesonephric-like Carcinoma
Elizabeth D. Euscher, Mario L. Marques‐Piubelli, Preetha Ramalingam, et al.
The American Journal of Surgical Pathology (2023) Vol. 47, Iss. 6, pp. 635-648
Closed Access | Times Cited: 13
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Rodrigo Entrialgo‐Cadierno, Cristina Cueto‐Ureña, Connor Welch, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer
Yongfeng Shang, Shengnan Fu, M. Pang, et al.
(2025)
Closed Access
A Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS Mutations
Abhimanyu Tushir, Israh Akhtar, Anjali Seth
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 1, pp. 66-66
Open Access
Prevalence and breakdown ofKRASdriver mutations in a large UK non-small cell lung cancer cohort
Isabella Niesner, Kevin Balbi, Benjamin Poskitt, et al.
Journal of Clinical Pathology (2025), pp. jcp-209972
Closed Access
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
James Cregg, Anne Edwards, Stephanie Chang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
A Novel Mouse Cell Line Model Reveals the Tumor Intrinsic and Immune Characteristics of EGFR-Mutant Lung Cancer
Yueren Yan, Jun Shang, Chunnan Liu, et al.
(2025)
Closed Access
Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity
Alexander Arthur Wurm, Silke Brilloff, Sofia Kolovich, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101200-101200
Open Access | Times Cited: 12
Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma
Jun Wang, Liwen Dong, Zhaowei Zheng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Kuen Kuen Lam, Siew Heng Wong, Peh Yean Cheah
Cells (2023) Vol. 12, Iss. 4, pp. 631-631
Open Access | Times Cited: 10
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Dan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4933-4933
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top